Literature DB >> 2991778

The interaction of canrenone with the Na+,K+ pump in human red blood cells.

R P Garay, J Diez, C Nazaret, G Dagher, J P Abitbol.   

Abstract

Canrenone inhibits 30-40% of ouabain-sensitive Na+ efflux in human red cells. Half-maximal inhibition was obtained with a canrenone concentration = 86 +/- 37 mumol/l (mean +/- SD of 13 experiments). The partial inhibition of the Na+,K+ pump appears to be mediated at the digitalis receptor site with an apparent dissociation constant (Kc) = 200 +/- 130 mumol/l (mean +/- SD). Further evidence suggesting that canrenone is a partial agonist at the digitalis receptor site was obtained by the observation that it decreases the apparent affinity of the Na+,K+ pump for external K+. However, in contrast to ouabain, canrenone decreases the apparent pump affinity for internal Na+. Our results show that, at physiological cell Na+ levels canrenone is able to enhance the inhibition of the Na+,K+ pump by low doses of ouabain. Conversely, in cells treated with high concentrations of cardiac glycosides (in which cell Na+ content increases), canrenone is able to restimulate the blocked pumps.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991778     DOI: 10.1007/bf00501886

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  19 in total

1.  Interaction of spironolactone and digoxin in dogs.

Authors:  G E Musgrave; C K Born; C P Davidson; M E Hamrick
Journal:  J Pharmacol Exp Ther       Date:  1977-09       Impact factor: 4.030

2.  The interaction of sodium and potassium with the sodium pump in red cells.

Authors:  R P Garay; P J Garrahan
Journal:  J Physiol       Date:  1973-06       Impact factor: 5.182

3.  Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

Authors:  W Sadée; M Dagcioglu; R Schröder
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

Review 4.  The red cell membrane and the transport of sodium and potassium.

Authors:  J F Hoffman
Journal:  Am J Med       Date:  1966-11       Impact factor: 4.965

Review 5.  Renal target sites and the mechanism of action of aldosterone.

Authors:  D Marver; J P Kokko
Journal:  Miner Electrolyte Metab       Date:  1983 Jan-Feb

6.  The effect of ouabain on noradrenaline output from peripheral adrenergic neurones of isolated guinea-pig vas deferens.

Authors:  Y Nakazato; A Ohga; Y Onoda
Journal:  J Physiol       Date:  1978-05       Impact factor: 5.182

7.  Potentiating and depressive effects of ouabain and potassium-free solutions on rat mesenteric resistance vessels.

Authors:  M J Mulvany; H Nilsson; J A Flatman; N Korsgaard
Journal:  Circ Res       Date:  1982-10       Impact factor: 17.367

8.  The sensitivity of the sodium pump to external sodium.

Authors:  P J Garrahan; I M Glynn
Journal:  J Physiol       Date:  1967-09       Impact factor: 5.182

9.  Positive inotropic effect of K-canrenoate: an investigation in anaesthetized dogs, untreated or treated with digitalis.

Authors:  G Marchetti; E Vitolo; G F Di Francesco; B Cavallaro; C Sponzilli
Journal:  Arch Int Pharmacodyn Ther       Date:  1983-12

10.  Negative inotropic effects of aldosterone antagonists in isolated human and guinea-pig ventricular heart muscle.

Authors:  A Mügge; W Schmitz; H Scholz
Journal:  Klin Wochenschr       Date:  1984-08-01
View more
  3 in total

Review 1.  Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.

Authors:  Alexei Y Bagrov; Joseph I Shapiro; Olga V Fedorova
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

2.  High sensitivity of the Na+, K+-pump of human red blood cells to genins of cardiac glycosides.

Authors:  N Senn; L G Lelièvre; P Braquet; R Garay
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

3.  Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.

Authors:  Jiang Tian; Amjad Shidyak; Sankaridrug M Periyasamy; Steven Haller; Mohamed Taleb; Nasser El-Okdi; Jihad Elkareh; Shalini Gupta; Sabry Gohara; Olga V Fedorova; Christopher J Cooper; Zijian Xie; Deepak Malhotra; Alexei Y Bagrov; Joseph I Shapiro
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.